Japan subset of Phase III study KEYNOTE-024: Pembrolizumab for PD-L1 TPS > =50%, treatment-naïve NSCLC

Miyako Satouchi, Katsuyuki Hotta, Kaname Nosaki, Toshiaki Takahashi, Kazuhiko Nakagawa, Keisuke Aoe, Kazuo Noguchi, Takashi Shimamoto, Reshma Rangwala, Julie Brahmer

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)ix73
JournalAnnals of oncology : official journal of the European Society for Medical Oncology
Volume28
DOIs
Publication statusPublished - Oct 1 2017

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this